Robeco Institutional Asset Management B.V. Sells 19,161 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Robeco Institutional Asset Management B.V. lowered its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 167,356 shares of the specialty pharmaceutical company’s stock after selling 19,161 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.27% of Jazz Pharmaceuticals worth $18,645,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of JAZZ. Capital World Investors bought a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $171,943,000. Swedbank AB acquired a new stake in Jazz Pharmaceuticals in the second quarter worth $106,936,000. Rubric Capital Management LP bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth $65,812,000. Pacer Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after buying an additional 527,187 shares during the period. Finally, Baupost Group LLC MA increased its position in shares of Jazz Pharmaceuticals by 52.8% in the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after buying an additional 440,552 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on JAZZ. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Piper Sandler decreased their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Morgan Stanley dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Finally, HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $173.43.

Jazz Pharmaceuticals Stock Up 0.1 %

JAZZ stock opened at $111.55 on Thursday. The company has a market cap of $6.89 billion, a price-to-earnings ratio of 19.17, a P/E/G ratio of 1.37 and a beta of 0.57. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.48. The business has a 50 day moving average price of $110.42 and a two-hundred day moving average price of $109.61. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.